Search research articles
Contact Us
Filters
Showing results (161-170 of 218) with videos related to
Page
of 22
Sort By:
The Lancet. Oncology
|
April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
November 9, 2021
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer
Caspar Franck, Nadja Zimmermann, Elisabetta Goni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2022
Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Journal of Cancer Research and Clinical Oncology
|
February 16, 2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care
Carl Christoph Schimanski, Frank Staib, Thomas Göhler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
Advances in Therapy
|
March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
Markus Moehler, Do-Youn Oh, Ken Kato, et al.
Frontiers in Oncology
|
August 29, 2022
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials
Matthew Ledenko, Samuel O Antwi, Shiho Arima, et al.
International Journal of Cancer
|
December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Arndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 218) with videos related to
Sort By:
Page
of 22
The Lancet. Oncology
|
April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Ralf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
November 9, 2021
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer
Caspar Franck, Nadja Zimmermann, Elisabetta Goni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2022
Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Journal of Cancer Research and Clinical Oncology
|
February 16, 2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care
Carl Christoph Schimanski, Frank Staib, Thomas Göhler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
Advances in Therapy
|
March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
Markus Moehler, Do-Youn Oh, Ken Kato, et al.
Frontiers in Oncology
|
August 29, 2022
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials
Matthew Ledenko, Samuel O Antwi, Shiho Arima, et al.
International Journal of Cancer
|
December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Arndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Page
of 22